Navigation Links
AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
Date:6/25/2013

aque and is now starting human studies in pursuit of these same successful results.

About AtheroNova

AtheroNova Inc. is a biotechnology company focused on the discovery, research, development and licensing of novel compounds to safely reduce or regress atherosclerotic plaque deposits and improve lipid profiles in humans. In addition to its lead compound AHRO-001, AtheroNova plans to develop multiple applications for its patented and patents-pending therapies in market sectors that include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis. Atherosclerosis and its related pharmaceutical expenses for these indications cost consumers more than $41 billion annually in the United States alone. For more information, please visit www.AtheroNova.com.

About OOO CardioNova

OOO CardioNova is an operational company in the Russian Federation founded by Maxwell Biotech Group to conduct clinical trials of AHRO-001, seek its approval, and then commercialize it in the territories covered by the license agreement.

About Maxwell Biotech Group

Maxwell Biotech Group is a development partner and financial resource for biotechnology companies. Maxwell provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Maxwell's unique business model can add value to its partners' pipelines and provide a commercialization path to one of the most lucrative emerging markets. Maxwell relies on an experienced international team of managers and financial and industry experts, with offices in Moscow, Boston and San Diego
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AtheroNova Announces Milestone Filing of IND in Russian Federation
2. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
5. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
6. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
7. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
8. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
9. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
10. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
11. Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... -- Landauer, Inc. (NYSE: LDR ), a recognized ... outsourced medical physics services and high quality medical consumable ... its President and Chief Executive Officer, will be stepping ... a member of the Board of Directors, effective as ... an interim basis by Michael T. Leatherman , ...
(Date:8/21/2014)... GREENWICH, Conn. , Aug. 21, 2014 /PRNewswire/ ... West Lafayette, Indiana , has ... determination and characterization of small and large molecules, ... addition of the Bruker maXisPlus Q-TOF mass spectrometer. ... Jonathan Goldman , CEO, Aptuit, said, "The expanded ...
(Date:8/21/2014)... DEERFIELD, Ill. , Aug. 21, 2014 /PRNewswire/ ... reports Baxter International Inc. today announced positive results ... BAX 855, an investigational, extended half-life recombinant factor ... ADVATE [Antihemophilic Factor (Recombinant)], which met its primary ... the prophylaxis arm compared to the on-demand arm. ...
Breaking Medicine Technology:Landauer, Inc. Announces Executive Management Change 2Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... , LONDON , January 19 The ... later today. , The ShelterBox Response Team of David ... have been in Haiti,s capital since Thursday, took,delivery of the first ShelterBoxes ... twelve of these boxes will be used to build an emergency,field hospital at the ...
... , THE WOODLANDS, Texas , Jan. 19 ... changing its name to the Life Beyond Cancer Foundation. This new ... to provide to cancer patients and their families. , The ... removing barriers to prevention, education, early detection, treatment and survivorship. Cancer ...
Cached Medicine Technology:First ShelterBoxes Arrive in Port au Prince - Pictures and Footage 2US Oncology Foundation Becomes Life Beyond Cancer Foundation 2US Oncology Foundation Becomes Life Beyond Cancer Foundation 3
(Date:8/22/2014)... A new study of self-awareness by Kessler ... (MS) may be able to improve their self-awareness ... ahead of print on July 2 in ... Nancy D. Chiaravalloti & John DeLuca: Metacognitive knowledge ... doi: 10.3233/NRE-141113). Self-awareness is one,s ability to recognize ...
(Date:8/22/2014)... attained the distinguished Magnet hospital designation by the ... Considered the gold standard for nursing excellence, the ... professionalism. It is the top international credential for ... Newport Hospital was based on the hospital,s continued ... , "It is a privilege for us to ...
(Date:8/22/2014)... Counseling may do little to help young people with ... 66 studies that included nearly 18,000 people 25 and ... drinking problems. Participants in 49 studies attended a single ... the studies attended group sessions or a mix of ... motivational interviewing was used in the studies. This technique ...
(Date:8/22/2014)... treatments have become available for key subtypes of ... treatments can be pre-identified by looking for defined ... whose lung cancer is driven by rearrangement of ... drug crizotinib, which targets this abnormality. Many ongoing ... success by matching different drugs with specific subtypes ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 ItsHot.com, a ... now offering 60-80% off on its range of beautiful ... the purchase of Gold Hearts 14K White Rose Gold ... a discount of 77%. Previously priced at $3,715.00, ... $859.00. The item code of this mesmerizing pendant embedded ...
Breaking Medicine News(10 mins):Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4Health News:ItsHot.com Now Offers 60-80% Discount on its Striking Collection of Diamond Heart Pendants 2
... new study reveals that almost two-thirds of US ... life, but very few of them experience post-traumatic ... emotional resilience in children, but it also suggests that ... adults, said William Copeland of Duke University Medical Center, ...
... Mayfield Dairy Farms announced today that it is voluntarily recalling ... a code date of 4/11/08 and a UPC code ... contains peanuts, which are not listed on the label. No ... ,Some individuals with allergies to peanuts run the ...
... Higher Colon Cancer Risk in Uveal Melanoma Patients and ... by Frederick H. Davidorf, MD, during the Association ... Meeting in Fort Lauderdale, Fla. ,The presentation ... p.m. to 4:45 p.m. in Hall B/C of the ...
... brown widow spider, a cousin to the well-known black widow, ... ,It is belongs to a group that is officially ... referred to as "fiddleback" spiders or "violin" spiders because of ... (fused head and thorax). ,The spiders are generally ...
... to over 76.6 million people over the age of 60. ... ministry, the country has 76,622,321 persons aged 60 and above. ... Uttar Pradesh tops the chart with 11.6 million elderly. ... has 5.7 million, Bihar and Tamil Nadu have 5.5 million ...
... Ministry of External Affairs, informed the Lok Sabha today that ... passports. ,At first these passports will be ... the end of 2007. Based on the experience gained from this ... the ordinary category by the end of 2008. , ...
Cached Medicine News:Health News:Two-thirds of US Children Experience Trauma, but Recover Fast 2Health News:Louisiana Residents Warned Against Brown Recluse Spiders 2
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
... The CSV-1000S test face is widely used ... evaluation. This test presents standard visual acuity from ... (6 and 12 cycles/degree) and a real-world driver's ... cataract documentation as it provides a standard acuity ...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
Medicine Products: